170 research outputs found
Do antioxidant vitamins protect against atherosclerosis? The proof is still lacking**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
No full text
Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial
No full textSupplemental material 1 for Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial
No full textSupplemental material 1 for Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial by Mukul Sharma, Robert G Hart, Eric E Smith, Jackie Bosch, Fei Yuan, Amparo Casanova, John W Eikelboom, Stuart J Connolly, Gloria Wong, Rafael Diaz, Patricio Lopez-Jaramillo, Georg Ertl, Stefan Störk, Gilles R Dagenais, Eva M Lonn, Lars Ryden, Andrew M Tonkin, John D Varigos, Deepak L Bhatt, Kelley RH Branch, Jeffrey L Probstfield, Jae-Hyung Kim, Jong-Won Ha, Martin O’Donnell, Dragos Vinereanu, Keith AA Fox, Yan Liang, Lisheng Liu, Jun Zhu, Nana Pogosova, Aldo P Maggioni, Alvaro Avezum, Leopoldo S Piegas, Katalin Keltai, Matyas Keltai, Nancy Cook Bruns, Scott Berkowitz and Salim Yusuf in International Journal of Stroke</p
Supplemental material 2 for Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial
No full textSupplemental material 2 for Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial by Mukul Sharma, Robert G Hart, Eric E Smith, Jackie Bosch, Fei Yuan, Amparo Casanova, John W Eikelboom, Stuart J Connolly, Gloria Wong, Rafael Diaz, Patricio Lopez-Jaramillo, Georg Ertl, Stefan Störk, Gilles R Dagenais, Eva M Lonn, Lars Ryden, Andrew M Tonkin, John D Varigos, Deepak L Bhatt, Kelley RH Branch, Jeffrey L Probstfield, Jae-Hyung Kim, Jong-Won Ha, Martin O’Donnell, Dragos Vinereanu, Keith AA Fox, Yan Liang, Lisheng Liu, Jun Zhu, Nana Pogosova, Aldo P Maggioni, Alvaro Avezum, Leopoldo S Piegas, Katalin Keltai, Matyas Keltai, Nancy Cook Bruns, Scott Berkowitz and Salim Yusuf in International Journal of Stroke</p
Increasing service through aggressive dealer inventory return policies
No full textIn this paper, manufacturer dealer return policies are examined for high volume part sales for long-life cycle products. Exclusive suppliers often use simple returns policies for high-value products to persuade their independent dealers to stock and price items aggressively. For low-value products, a return policy problem occurs; dealer requests for low-value returns are routinely rejected Because a manufacturer may make over 500 return request decisions per day, a fast algorithm is required. Two fast algorithms that evaluate multi pk factors are presented and tested for six months against dealer inventory requests at heavy equipment manufacturer, Caterpillar, Inc. The results show that the proposed algorithms may eliminate nearly 1,000 back-orders per month The results indicate that exclusive suppliers can modify their return policies to improve service to customers by analysing not only product value, but also inventory level and lead-time.Journal Articl
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristic
No full textBackgroundThe ONTARGET and TRANSCEND clinical trials were designed to investigate the cardioprotective effects of telmisartan 80 mg and ramipril 10 mg, alone and in combination, in patients at high risk of cardiovascular disease. Cardiac MRI enables investigation of mechanistic effects of these agents on cardiac structural and functional variables. Here, we report the design, analysis protocol, reproducibility and relevant quality control procedures, and baseline patient characteristics of the ONTARGET/TRANSCEND cardiac MRI substudy. MRI was undertaken in 330 subjects enrolled in ONTARGET, and 38 subjects in TRANSCEND, across eight centers in six countries. Analyses were performed by two independent analysts using guide-point modeling. Cases with discrepancies in LV mass (LVM) of >5% were independently reanalyzed. Cases with discrepancies in end-diastolic volume (EDV) of >5%, or end-systolic volume (ESV) of >12%, were then reconciled by consensus.ResultsBaseline characteristics were broadly similar to the main ONTARGET/TRANSCEND trials, except for a higher frequency of coronary artery disease and Asian ethnicity in the substudy. Reproducibility of MRI analyses (mean +/- SD) were 2.8 +/- 3.7 ml in EDV, -0.3 +/- 3.6 ml in ESV, 3.1 +/- 3.3 ml in SV, 1.1 +/- 1.8% in EF, and 0.4 +/- 4.5 g in LVM. Subgroup analyses revealed increased ESV and LVM, and reduced EF, in subjects with a history of either coronary artery disease or myocardial infarction.ConclusionsThe ONTARGET/TRANSCEND cardiac MRI substudy protocol provides for a reliable assessment of the effects of telmisartan and ramipril, alone and in combination, on cardiac structural and functional parameters over a 2-year follow-up period.Brett R. Cowan, Alistair A. Young, Craig Anderson, Robert N. Doughty, Rungroj Krittayaphong, Eva Lonn, Thomas H. Marwick, Chris M. Reid, John E. Sanderson, Roland E. Schmieder, Koon Teo, Angela K. Wadham, Stephen G. Worthley, Cheuk-Man Yu, Salim Yusuf and Garry L. Jenning
PREDICTORS OF PHYSICAL FUNCTIONING FOLLOWING INTRAMEDULLARY NAILING OF TIBIAL SHAFT FRACTURES
No full textBackground: Tibial fractures are associated with prolonged recovery. The aim of this study was to identify predictors of long-term physical functioning after tibial shaft fracture.
Methods: We used data from the Trial to Re-evaluate Ultrasound in the Treatment of Tibial Fractures (TRUST) to determine, in patients with unilateral, open or closed tibial shaft fracture, the association between baseline factors and physical functioning at 1-year. All fractures were fixed using intramedullary nails. Physical functioning was measured using the 100-point Short Form-36 (SF-36) Physical Component Summary (PCS) score; higher is better; minimally important difference is 2 to 5 points.
Results: There were 299 tibial fracture patients with complete data available for analysis. In an adjusted analysis, the factors associated with lower physical functioning at 1-year were: (1) current smokers (mean difference [MD] -2.55, 95% confidence interval [95%CI] -4.63 to -0.46, p=0.017), (2) body mass index >30 kg/m² (MD -2.57, 95% CI -4.86, -0.27, p = 0.029), and (3) patients who were receiving disability benefits or involved in litigation, or planned to be (MD -2.65, 95% CI -4.58 to -0.72, p = 0.007). Patients who were employed at the time of their fracture reported significantly higher physical functioning at 1-year (MD 4.56, 95% CI 2.32 to 6.80, p= <0.001) and those who were allowed to partial or full weight-bear post-operatively (MD 1.98, 95% CI 0.13 to 3.82, p=0.036). Neither age, sex, fracture severity or receipt of physical therapy were associated with long-term physical functioning.
Conclusions: Among patients undergoing surgical repair of tibial fractures, partial or full weight-bearing post-operatively and employment at the time of injury predict better long-term functioning, whereas smoking, obesity, and receipt of disability benefits or involvement in litigation (or plans to be) predict worse long-term functioning.ThesisMaster of Science (MSc
Left ventricular mass and volume with Telmisartan, Ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])
No full textThe ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not inferior to the angiotensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than ramipril alone, in decreasing morbidity and mortality in patients with cardiovascular disease or high-risk diabetes. Although therapy targeting angiotensin II is known to decrease left ventricular (LV) mass and volume, the relative influence of angiotensin-converting enzyme inhibitor inhibitors and angiotensin receptor blocker, and their combination, on the heart remains unclear in this population. Magnetic resonance imaging was performed in 287 patients enrolled in ONTARGET, across 8 centers in 6 countries, at randomization and after 2-year treatment (90, 100, and 97 patients in the ramipril, telmisartan, and combination therapy groups, respectively). Baseline patient characteristics showed higher frequencies of coronary artery disease, Asian ethnicity, and use of statins and beta blockers than the main ONTARGET trial. LV mass decreased in all groups (p <0.0001 for each), but there were no significant differences in change in LV mass or volume among groups, except that LV mass index decreased more on combination versus telmisartan (p = 0.04). Key determinants of LV mass decrease were a history of hypertension (p = 0.03), baseline mass (p <0.0001), and decrease in systolic blood pressure (p <0.0001). The best magnetic resonance imaging predictor of composite events was end-systolic volume (p <0.0001). In conclusion, telmisartan and ramipril had similar effects on LV mass and volume, and combination therapy was not more effective, in high-risk patients with cardiovascular disease. These results are consistent with the major outcome findings of the main ONTARGET study.Brett R. Cowan, Alistair A. Young, Craig Anderson, Robert N. Doughty, Rungroj Krittayaphong, Eva Lonn, Thomas H. Marwick, Chris M. Reid, John E. Sanderson, Roland E. Schmieder, Koon Teo, Angela K. Wadham, Stephen G. Worthley, Cheuk-Man Yu, Salim Yusuf, Garry L. Jennings and ONTARGET Investigator
- …
